drugset / Trial / NCT02828319

Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia

NCT02828319 ↗

Phase 3 Completed 39 enrolled Zeria Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

To confirm the safety and efficacy of Z-213 until 12 weeks after start of Z-213 administration in patients with iron deficiency Anemia

Timeline

Start
2016-07
Primary completion
2017-05
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Z-213 Unknown — Intravenous